Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.11497
Abstract: Key Points Question Are certain demographic or clinical factors associated with a favorable vaccine response to tozinameran among rituximab-treated patients with multiple sclerosis? Findings In this cohort study of 67 patients with multiple sclerosis, among… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27318
Abstract: The findings of this study highlight a 95% accuracy rate in ChatGPT responses, as assessed by five myeloma specialists, underscoring its potential as a reliable educational tool. read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Annals of Neurology"
DOI: 10.1002/ana.26534
Abstract: Ocrelizumab, an anti‐CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2596
Abstract: Multiple sclerosis is a chronic demyelinating disease of the central nervous system that can cause severe disability and impair the quality of life (QoL). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34169
Abstract: BACKGROUND Given equivocal results related to overall survival (OS) for patients with multiple primary melanomas (MPMs) compared with those with single primary melanomas (SPMs) in previous reports, the authors sought to determine whether OS differs… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.22127
Abstract: Increasing indications for cellular therapy collections have stressed our healthcare system, with autologous collections having a longer than desired wait time until apheresis collection. This quality improvement initiative was undertaken to accommodate more patients within… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Molecular Genetics & Genomic Medicine"
DOI: 10.1002/mgg3.1921
Abstract: This study aimed to investigate the clinical and genetic spectrum in Chinese patients with multiple mtDNA deletions presenting with autosomal‐inherited mitochondrial progressive external ophthalmoplegia (PEO). read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.23101
Abstract: The Actionable Bladder Symptom and Screening Tool (ABSST) is used to identify multiple sclerosis (MS) patients in possible need of evaluation for urinary symptoms. The primary objective of this study was to identify barriers experienced… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.23173
Abstract: To assess the feasibility of using D‐mannose, a natural food supplement, in patients with multiple sclerosis (MS) reporting recurrent urinary tract infections (UTIs) as a preventative. read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.23921
Abstract: To systematically assess all available evidence on efficacy and safety of desmopressin for treating nocturia in patients with multiple sclerosis (MS). read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24279
Abstract: The objective of this study was to report the long‐term outcomes and complications of patients with multiple sclerosis (MS) who underwent noncontinent urinary diversion to treat lower urinary tract symptoms (LUTS). read more here.